Catalyst

Slingshot members are tracking this event:

Merrimack Pharmaceuticals (MACK) begins second Sarbox Phase 2 proof-of-concept study for MM-121 in postmenopausal metastatic breast cancer

Source Link:
https://seekingalpha.com/article/4071679-merrimack-pharmaceuticals-mack-ceo-dr-richard-peters-q1-2017-results-earnings-call-transcript?page=3

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MACK Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Feb 26, 2018
Occurred Source:
http://investors.merrimack.com/news-releases/news-release-details/merrimack-doses-first-patient-randomized-phase-2-clinical-study
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Sarbox, Mm-121, Postmenopausal Metastatic Breast Cancer Patie
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.